Evidence map›Paper›PMID 34051479›Full record

ArticleVirology2021

Live cell, image-based high-throughput screen to quantitate p53 stabilization and viability in human papillomavirus positive cancer cells.

Gustavo Martínez-Noël, Valdimara Corrêa Vieira, Patricia Szajner, Erin M Lilienthal, Rebecca E Kramer, Kathleen A Boyland, Jennifer A Smith, Peter M Howley

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Gustavo Martínez-NoëlDepartment of Immunology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115, USA.
Valdimara Corrêa VieiraDepartment of Immunology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115, USA.
Patricia SzajnerDepartment of Immunology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115, USA.
Erin M LilienthalICCB-Longwood Screening Facility, Harvard Medical School, 250 Longwood Avenue, Boston, MA, 02115, USA.
Rebecca E KramerDepartment of Immunology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115, USA.
Kathleen A BoylandDepartment of Immunology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115, USA.
Jennifer A SmithDepartment of Immunology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115, USA; ICCB-Longwood Screening Facility, Harvard Medical School, 250 Longwood Avenue, Boston, MA, 02115, USA.
Peter M HowleyDepartment of Immunology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115, USA. Electronic address: peter_howley@hms.harvard.edu.
Harvard University · US

Funding

Molecular Biology of Oncogenic PapillomavirusesR35CA197262 · NCI · HARVARD MEDICAL SCHOOL · PI HOWLEY, PETER M · 2016 to 2022
$7.1M
NCI NIH HHS R35 CA197262
6 · The paper itself

Abstract

Approximately 5% of cancers are caused by high-risk human papillomaviruses. Although very effective preventive vaccines will reduce this cancer burden significantly over the next several decades, they have no therapeutic effect for those already infected and remaining at risk for malignant progression of hrHPV lesions. HPV-associated cancers are dependent upon the expression of the viral E6 and E7 oncogenes. The oncogenic function of hrHPV E6 relies partially on its ability to induce p53 degradation. Since p53 is generally wildtype in hrHPV-associated cancers, p53 stabilization arrests proliferation, induces apoptosis and/or results in senescence. Here we describe a live cell, image-based high-throughput screen to identify compounds that stabilize p53 and/or affect viability in HPV-positive cancer HeLa cells. We validate the robustness and potential of this screening assay by assessing the activities of approximately 6,500 known bioactive compounds, illustrating its capability to function as a platform to identify novel therapeutics for hrHPV.

Indexed as

ApoptosisAurora KinasesCell Line, TumorCell ProliferationCyclin-Dependent KinasesDNA-Binding ProteinsFemaleHeLa CellsHigh-Throughput Screening AssaysHistone Deacetylase InhibitorsHuman papillomavirus 18HumansOncogene Proteins, ViralPapillomavirus InfectionsTopoisomerase InhibitorsTumor Suppressor Protein p53Aurora KinasesCyclin-Dependent KinasesDNA-Binding ProteinsE6 protein, Human papillomavirus type 18E7 protein, Human papillomavirus type 18Histone Deacetylase InhibitorsOncogene Proteins, ViralTopoisomerase InhibitorsTP53 protein, humanTumor Suppressor Protein p53Cervical cancerE6APE6 oncoproteinHigh-throughput screenHuman papillomavirusp53Small molecule

Identifiers

PMID34051479
PMCPMC8206038
OpenAlexW3164519303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.